20 Jul Outpace Bio
Marc Lajoie, Ph.D., CEO
Oct. 8 | 9:00am | FLW Ballroom F
Seattle, WA
(Private)
OUTPACE is a Seattle based biotech using unrivaled AI-powered protein design to deliver on the promise of cell therapy by programming cells for improved function inside the patient. The company designs proteins that mechanistically solve the key barriers to efficacy in solid tumors (poor access to the tumor, weak survival, rapid inactivation, antigen escape, and high required doses drive toxicity) and encodes them into the cell therapy using standard manufacturing processes. Leveraging this powerful platform, in one year the company constructed its lead program, OPB-101, which robustly cures solid tumor xenograft models with two orders of magnitude better efficacy than other programs in the clinic, driven by an ability to expand and functionally persist in stringent solid tumor models. Based on its tumor-localized activity and low required cell dose, OPB-101 has the potential to offer an exceptional therapeutic index. Outpace is on track to submit its first IND in 2024.
